---
title: "Larimar Therapeutics, Inc. (LRMR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LRMR.US.md"
symbol: "LRMR.US"
name: "Larimar Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T11:53:21.484Z"
locales:
  - [en](https://longbridge.com/en/quote/LRMR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LRMR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LRMR.US.md)
---

# Larimar Therapeutics, Inc. (LRMR.US)

## Company Overview

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.larimartx.com](https://www.larimartx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.22 | 259 | - | - | - |
| PB | 2.33 | 209 | 3.59 | 2.35 | 1.82 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 89% |
| Overweight | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.53 |
| Highest Target | 26.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LRMR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LRMR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LRMR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LRMR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**